Danaher (NYSE:DHR) Earns “Outperform” Rating from Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Danaher (NYSE:DHR) in a research report released on Thursday morning,Benzinga reports. The firm currently has a $277.00 price objective on the conglomerate’s stock, down from their prior price objective of $299.00.

Other research analysts also recently issued research reports about the stock. Raymond James dropped their price objective on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Guggenheim assumed coverage on shares of Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price for the company. Wells Fargo & Company dropped their target price on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday. Finally, Citigroup lowered their price target on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a report on Monday, January 6th. Six research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Danaher has an average rating of “Moderate Buy” and an average price target of $278.00.

Danaher Stock Performance

Shares of NYSE DHR opened at $223.16 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a market cap of $161.19 billion, a PE ratio of 42.27, a price-to-earnings-growth ratio of 4.22 and a beta of 0.83. The company has a 50-day simple moving average of $235.89 and a 200-day simple moving average of $253.45. Danaher has a 12 month low of $221.34 and a 12 month high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.72% and a net margin of 16.33%. During the same period in the prior year, the firm posted $2.09 earnings per share. On average, equities analysts anticipate that Danaher will post 8.15 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.48%. Danaher’s dividend payout ratio is 20.45%.

Hedge Funds Weigh In On Danaher

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wedge Capital Management L L P NC grew its holdings in shares of Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 38 shares during the last quarter. Meridian Financial Partners LLC raised its holdings in shares of Danaher by 4.4% in the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after acquiring an additional 40 shares in the last quarter. Kovack Advisors Inc. grew its holdings in Danaher by 3.4% during the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after acquiring an additional 41 shares in the last quarter. Well Done LLC raised its holdings in shares of Danaher by 1.2% in the 3rd quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock valued at $987,000 after purchasing an additional 42 shares in the last quarter. Finally, Waypoint Capital Advisors LLC boosted its stake in shares of Danaher by 0.9% during the third quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock valued at $1,257,000 after purchasing an additional 42 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.